These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25658233)

  • 21. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
    Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
    Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.
    Heinrich D; Bruland Ø; Guise TA; Suzuki H; Sartor O
    Future Oncol; 2018 Oct; 14(24):2543-2556. PubMed ID: 29925281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
    Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
    J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
    Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
    Karzai FH; Madan RA; Figg WD
    South Med J; 2015 Apr; 108(4):224-8. PubMed ID: 25871992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
    Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
    Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
    Li J; Gregory SG; Garcia-Blanco MA; Armstrong AJ
    Crit Rev Clin Lab Sci; 2015; 52(4):191-210. PubMed ID: 26079252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.
    Kienel A; Porres D; Heidenreich A; Pfister D
    J Urol; 2015 Oct; 194(4):966-71. PubMed ID: 25896555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
    Izumi K; Shigehara K; Nohara T; Narimoto K; Kadono Y; Mizokami A
    Anticancer Res; 2017 Oct; 37(10):5559-5564. PubMed ID: 28982870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumour cells-monitoring treatment response in prostate cancer.
    Miyamoto DT; Sequist LV; Lee RJ
    Nat Rev Clin Oncol; 2014 Jul; 11(7):401-12. PubMed ID: 24821215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on "Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer".
    Chueh SC
    South Med J; 2015 Apr; 108(4):229. PubMed ID: 25871993
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Navigating the evolving therapeutic landscape in advanced prostate cancer.
    Crawford ED; Petrylak D; Sartor O
    Urol Oncol; 2017 May; 35S():S1-S13. PubMed ID: 28283376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Testosterone in the management of metastatic prostate cancer].
    Wolff JM; Schmid HP
    Urologe A; 2015 Nov; 54(11):1578-83. PubMed ID: 26113300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.